

# European Survey to explore the impact of epileptic encephalopathy KCNQ2 in the daily lives of affected patients.

An iniziativa of:

- EUROPEAN KCNQ2 ASSOCIATION
- KCNQ2 Einblick, Beratung, Netwerk Germany
- ASOCIACION KCNQ2 ESPANA
- KCNQ2 FRANCE
- DRAVET ITALIA ONLUS


With the support of CREP Centro Ricerca Epilessie in età Pediatriche - Verona

# Preliminary Data Survey KCNQ2


Survey translate in 5 languages ad disseminate in all word by the national associations.

Italian Version: divided in 2 times (2020 December 20 to 2021 January 10 and 2021 February 10 to March 30.)

English French, German and Spanish Version opened from 2021 February 10 to March 30.



# Preliminary Data Survey KCNQ2





Centro Ricerca per le Epilessie  
in età Pediatrica




# Preliminary Data Survey KCNQ2

Dr. Tommaso Lo Barco & Prof. Francesca Darra

## What we already know about KCNQ2 Encephalopathy:

- It's a Developmental and Epileptic Encephalopathy with seizures starting in first days of life


### SEIZURES 65/68 ONSET AGE




## What we already know about KCNQ2 Encephalopathy:

- Mutation is almost always *de novo*

At what age was the genetic diagnosis performed?




Have genetic investigations been extended / carried out to parents as well?




## What we already know about KCNQ2 Encephalopathy: - Seizures usually stop during first 4 years of life

How often do seizures occur today?  
In 65 pts with seizures

**MEDIAN AGE 6**



## Comorbidities variously associated 54/68 pts




- Gastrointestinal complications
- Orthopedic complication
- Urinary problems
- Breathing problems
- Dermatological problems
- Endocrinological problems

# In conclusion..

- This is the largest family survey performed on patients with KCNQ2 encephalopathy.
- It represents a unique chance to collect information regarding daylife of individuals affected by this rare condition.
- By analysing acquired data in different groups of age, we can try and delineate natural history (epilepsy trend, neurological outcome, personal autonomies)
- This would help to:
  - Individuate possible subgroups of patients with worst/better outcome
  - Define treatment outcomes (rehabilitation/pharmacological/...gene therapy?) other than seizures
  - Raise the attention on the family burden.

# Thanks for the attention



World Health Organization

SEVENTY-THIRD WORLD HEALTH ASSEMBLY  
Agenda item 11.6

A73/A/CONF./2  
9 November 2020

**Global Actions on epilepsy and other  
neurological disorders**

**Draft resolution proposed by Belarus, Bhutan, China, Colombia,  
Eswatini, the European Union and its Member States, Guyana,  
Iceland, Jamaica, Philippines, Russian Federation**